Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in COPD or cystic fibrosis
2019-000955-16Phase 4Active
- Sponsor
- Medical University of Vienna
- Start
- Jan 2020
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piperacillin, tazobactam and levofloxacin in pneumonia, sponsored by Medical University of Vienna. Started Jan 2020; status: active.
02
Drugs
03
Conditions
pneumonia
Beyond the preview
Go deeper on 2019-000955-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000955-16.